Abstract: The present disclosure relates to the use of LRRC4 family mimic molecules to determine the expression level of FAM19A5 protein in a subject. In some aspects, such mimic molecules can be used to identify and/or diagnose a subject suffering from or at risk of developing a disease or disorder associated with increased FAM19A5 protein expression. The present disclosure also provides methods of treating subjects identified and/or diagnosed using the methods provided herein.

Abstract: A composition containing wall teichoic acid-attached peptidoglycan (WTA-PGN) as an active ingredient, a method for preventing or treating Staphylococcus aureus infectious diseases using the composition, and a method for preparing a soluble WTA-PGN which can be used as an active ingredient in the composition are provided. The composition of the present invention can be effectively used for preventing or treating Staphylococcus aureus infectious diseases by opsonophagocytosis due to antigen-antibody reaction and neutrophil-mediated phagocytosis due to T cell activation at the early stage of infection.